Novartis (NYSE:NVS) unit Sandoz said this week that Pear Therapeutics will take sole responsibility for the commercialization of their prescription digital therapeutics program for treating substance and opioid use disorders.
In April 2018, Pear announced that it agreed to deal commercialization rights of its digital therapeutics to Sandoz. The companies did not disclose financial details, but Boston-based Pear Therapeutics said the agreement included an upfront payment, R&D funding, commercial milestones and a profit split on net sales.
Get the full story at our sister site, Drug Delivery Business News.